{"entity":{"id":"michael-kerin","kind":"person","name":"Michael Kerin","aka":[],"tldr":"Professor who is Clinical Director of the Saolta Cancer Managed Clinical Academic Network, the cancer centre serving the west and north west of Ireland from Galway.","summary":"Professor Michael Kerin is Clinical Director of the Saolta Cancer Managed Clinical Academic Network (Saolta Cancer MCAN), the cancer programme of the Saolta University Health Care Group centred on University Hospital Galway and linked with the University of Galway. The Saolta cancer centre page names him in that role in connection with his commentary on new breast cancer screening technology. The Galway centre is one of Ireland's designated cancer centres and provides cancer services for the HSE West and North West region.","asOf":"2026-09-10","links":[{"label":"Source: Saolta cancer centre page naming the Clinical Director","url":"https://www.saolta.ie/cancer-centre"}],"tags":["leadership","clinician-scientist","comprehensive-cancer-centre"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["galway-university-hospital-cancer-centre"],"pathways":[],"terms":["screening"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Clinical Director, Saolta Cancer Managed Clinical Academic Network (Saolta Cancer MCAN), Galway University Hospitals","institutionId":"galway-university-hospital-cancer-centre","specialisms":["Breast cancer","Cancer network leadership","Academic medicine"],"profiles":[{"label":"Saolta cancer centre page","url":"https://www.saolta.ie/cancer-centre"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kerin+MJ%5BAuthor%5D"}],"papers":[{"title":"Clinicopathological response to neoadjuvant therapies and pathological complete response as a biomarker of survival in human epidermal growth factor receptor-2 enriched breast cancer – A retrospective cohort study","journal":"The Breast","year":2021,"doi":"10.1016/j.breast.2021.06.005"},{"title":"Clinicopathological and prognostic significance of programmed cell death ligand 1 expression in patients diagnosed with breast cancer: meta-analysis","journal":"British Journal of Surgery","year":2021,"doi":"10.1093/bjs/znab103"},{"title":"Clinicopathological correlates, oncological impact, and validation of Oncotype DX™ in a European Tertiary Referral Centre","journal":"The Breast Journal","year":2021,"doi":"10.1111/tbj.14217"}],"orcid":"0000-0003-4164-5561"},"route":"/people/michael-kerin/","neighbours":{"institution":[{"id":"galway-university-hospital-cancer-centre","kind":"institution","name":"University of Galway / Saolta Cancer Centre","route":"/institutions/galway-university-hospital-cancer-centre/"}],"term":[{"id":"screening","kind":"term","name":"Screening","route":"/terms/screening/"}]}}